Overview

Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF Infusion

Status:
Enrolling by invitation

Trial end date:
2024-10-01

Target enrollment:

Participant gender:

Summary

This is a non-randomized open-label extension study for subjects having completed protocol DA071976. Completed will be defined as either completing week 156 of DA071976, CLN100P.01, or withdrawal early to enter directly into this protocol.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Cerebral Therapeutics LLC

Treatments:

Valproic Acid